Simultaneous quantification of multiple proteins in user-defined tissue regions of interest
Patent Information
- Application Number
- CN201680054079.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2016-04-15
- Filing Date
- 2016-07-15
- Publication Date
- 2026-11-03
- Estimated Expiration
- 2036-07-15
AI Technical Summary
现有技术难以在用户定义的组织区域、细胞和细胞内亚细胞结构中同时、多路复用检测和定量多种蛋白质表达,且标准方法限于检测3-4种靶标。
Using probes containing target-binding domains and signal oligonucleotides, the signal oligonucleotides are released via photolysis technology, and digital counting is performed using the nCounter® system, enabling multiplexing detection and quantification of multiple protein expressions.
It enables the simultaneous detection and quantification of up to 800 protein targets in user-defined tissue regions, improving multiplexing capabilities and the reliability and consistency of detection, and supporting multi-center result comparison.
Smart Images

Figure CN108350483B_ABST
Abstract
Description
[0001] Cross-reference of related applications This application claims priority to U.S. Provisional Application No. 62 / 193819, filed July 17, 2015; U.S. Provisional Application No. 62 / 261654, filed December 1, 2015; U.S. Provisional Application No. 62 / 277283, filed January 11, 2016; and U.S. Provisional Application No. 62 / 323018, filed April 15, 2016. Each of the foregoing applications is incorporated herein by reference in its entirety. Background of the Invention Standard immunohistochemical methods allow for the simultaneous detection of up to 6-10 protein targets, typically 3-4 targets. There is a need for probes, compositions, methods, and kits for the simultaneous, multiplexed detection and quantification of protein expression in user-defined tissue regions, user-defined cells, and / or user-defined intracellular subcellular structures. Invention Overview This invention relates to probes, compositions, methods, and kits for the simultaneous, multiplexed detection and quantification of protein expression in user-defined tissue regions, user-defined cells, and / or user-defined intracellular subcellular structures.
[0004] One aspect of the invention relates to a method comprising the steps of: (1) contacting at least one protein target in or from at least one cell in a tissue sample with at least one probe comprising a target-binding domain and a signaling oligonucleotide; (2) applying a force sufficient to release the signaling oligonucleotide to a location in the tissue sample; and (3) collecting and identifying the released signaling oligonucleotide to detect at least one protein target at or from a specific location in the tissue sample from which the force was applied. The specific location is a user-defined tissue region, a user-defined cell, and / or a user-defined intracellular subcellular structure. The target-binding domain comprises a protein-binding molecule, such as an antibody, peptide, aptamer, or peptoid. In embodiments, two or more protein targets are detected. In the implementation scheme, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 or more targets, and any number thereof, for example, 800 or more different targets may be detected. In the implementation scheme, detection includes quantifying the abundance of each target.
[0005] In some embodiments, the method further includes repeating at least steps (2) and (3) at at least a second specific location in a tissue sample, the second specific location containing at least a second cell. In some embodiments, the detection includes comparing the abundance of at least one protein target at or from a first specific location with that at or from at least a second specific location. The at least one cell and the at least second cell may be the same cell type or different cell types. In some embodiments, the detection includes quantifying the abundance of at least one protein target at or from a first cell type with that at least a second cell type. In some embodiments, the first and second cell types are independently selected from normal cells and abnormal cells, such as diseased and cancerous cells.
[0006] In this embodiment, the at least one cell is directly fixed to the surface or indirectly fixed to the surface via at least one other cell. The tissue sample may be a tissue section 2-1000 μm thick, for example, derived from a formalin-fixed paraffin-embedded (FFPE) sample or from an unfixed sample. The at least one cell may be fixed or unfixed. The at least one cell may be stained or labeled prior to step (2) to visualize subcellular or cellular structures within the stained or labeled cell. Alternatively, for tissue sections, sections adjacent to the section in contact with the probe may be stained or labeled prior to step (2) to enable evaluation of subcellular, cellular, or tissue-related structures within the corresponding cells or nearby cells in the section in contact with the probe. Such staining or labeling techniques are well known in the art.
[0007] In the above respects, at least one probe further includes a linker (e.g., a cleavable linker) located between the target-binding domain and the signal oligonucleotide. The cleavable linker may be photocleavable, provided by a suitable coherent light source (e.g., laser and UV light sources) or a suitable incoherent light source (e.g., arc lamp and light-emitting diode (LED)). The light source may irradiate at least one subcellular structure of at least one cell and may detect the abundance of at least one protein target in or from at least one subcellular structure of at least one cell. Furthermore, the light source may first irradiate at least one subcellular structure in at least one cell and subsequently irradiate at least one subcellular structure in at least one second cell, enabling a comparison of the abundance of at least one protein target in or from at least one subcellular structure of at least one cell with that of at least one subcellular structure in at least one second cell.
[0008] In the implementation plan, the signal oligonucleotide is a single-stranded nucleic acid or a partially double-stranded nucleic acid.
[0009] In the implementation scheme, the sample may be cultured cells or dissociated cells (fixed or unfixed) fixed on a glass slide. The sample may contain cells (including both primary cells and cultured cell lines) and / or tissues (including cultured or transplanted tissues). The sample may contain cultured cells, primary cells, or dissociated cells from explants.
[0010] In implementation, illuminating a target area smaller than the field of view (e.g., a single cell or a subcellular structure within a cell) includes using a laser scanning device (e.g., a confocal one) or a digital mirror device (DMD) to guide the light.
[0011] In this embodiment, the probe is prepared by a cysteine bioconjugation method, which is stable and preferably site-specific to the hinge region heavy chain of the antibody. In this embodiment, the probe may contain multiple (i.e., more than one, e.g., 2, 3, 4, 5 or more) labeled oligonucleotides / antibodies.
[0012] Detection methods include polymerase reactions, reverse transcriptase reactions, hybridization with oligonucleotide microarrays, mass spectrometry, hybridization with fluorescent molecular beacons, sequencing reactions, or nCounter® molecular barcodes. In a preferred embodiment, the nCounter® system and methods from NanoString Technologies® are used.
[0013] In the implementation scheme, the signaling oligonucleotides are self-collected via laminar, turbulent, or transitional liquid flow. The flow can be via channels having a depth of 25–500 μm, for example, between the tissue and a fluid device or impermeable barrier placed above the tissue.
[0014] In this embodiment, the signal oligonucleotide is collected from a solution adjacent to (e.g., at least immediately above) at least one cell. The adjacent solution can be collected by aspiration, for example, via a pipette, capillary, microarray needle, flow cell, or another suitable aspiration system known in the art, or any combination thereof. The capillary may include an optical device capable of transmitting light (e.g., UV light) to at least one cell. The pipette or microarray needle may be attached to an array comprising a plurality of pipettes or microarray needles. The adjacent solution may contain an anionic polymer (e.g., dextran sulfate) and / or salmon sperm DNA, and / or the collected signal oligonucleotide may be added to a solution containing an anionic polymer such as dextran sulfate and / or salmon sperm DNA. Other nonspecific blocking agents known in the art may be used in addition to or instead of salmon sperm DNA.
[0015] In the implementation scheme, the method provides for simultaneous spatially resolved protein detection of tissue samples.
[0016] In the implementation scheme, the digital readings include a linear dynamic range greater than or equal to 5 log.
[0017] In the implementation scheme, the probe is provided to the sample at a concentration generally lower than that used for immunohistochemistry (IHC) or in situ hybridization (ISH). Alternatively, the concentration may be significantly lower than that used for IHC or ISH. For example, the probe concentration may be as low as 1 / 2, 1 / 5, 1 / 10, 1 / 20, 1 / 25, 1 / 30, 1 / 50, 1 / 60, 1 / 70, 1 / 80, 1 / 90, 1 / 100, 1 / 200, 1 / 300, 1 / 400, 1 / 500, 1 / 600, 1 / 700, 1 / 800, 1 / 900, 1 / 1000, 1 / 2000 or lower and any number in between. In the implementation scheme, the probe is provided at concentrations of 100 nM, 70 nM, 60 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 0.9 nM, 0.8 nM, 0.7 nM, 0.6 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.2 nM, 0.1 nM, 0.09 nM, 0.08 nM, 0.07 nM, 0.06 nM, 0.05 nM, 0.04 nM, 0.03 nM, 0.02 nM, 0.01 nM and lower, and any concentrations in between.
[0018] In one implementation, a tissue sample is attached to a glass slide and first imaged using fluorescence (e.g., fluorescently labeled antibodies and fluorescent dyes (e.g., DAPI)), followed by a digital count of protein expression from the sample.
[0019] In embodiments, negative purification is used to remove intact probe molecules from self-releasing signaling oligonucleotides. Negative purification includes, for example, affinity purification methods, involving contacting the intact probe molecule with an immobilized oligonucleotide or immobilized antibody complementary to a portion of the intact probe, or a protein-binding motif that recognizes and binds to a portion of the intact probe. In embodiments, the target-binding domain of the intact probe contains a universal purification tag or a sequence complementary to the immobilized oligonucleotide portion or capable of being recognized or bound by the immobilized antibody or protein-binding motif. Any such tag or sequence known in the art can be used in these embodiments.
[0020] Any aspect or embodiment described herein may be combined with any other aspect or embodiment disclosed herein. Although this disclosure has been described together with its detailed description, the foregoing description is intended to illustrate and not limit the scope of this disclosure as defined by the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.
[0021] The patents and scientific literature referenced herein establish knowledge available to those skilled in the art. All U.S. patents and published or unpublished U.S. patent applications cited herein are incorporated by reference. All published foreign patents and patent applications cited herein are incorporated by reference. All other published references, documents, manuscripts, and scientific literature cited herein are incorporated by reference. Brief description of the attached diagram The patent or application documents contain at least one color drawing. A copy of the color drawing published in this patent or patent application will be provided by the International Bureau upon request and after payment of the necessary fees.
[0023] Figure 1 Two exemplary probes are shown. The nucleic acid backbone (single-stranded DNA or single-stranded RNA) is shown as a black straight line. Each probe includes a target-binding domain shown in red. The upper probe includes a labeled RNA fragment hybridized to the nucleic acid backbone, while the lower probe includes a labeled DNA oligonucleotide hybridized to the nucleic acid backbone. A cleavable motif (e.g., a cleavable adapter, not shown) may be located between or within the backbone and the target-binding domain. The cleavable motif enables the self-binding target nucleic acid or protein to release a signal oligonucleotide, which is then collected and detected.
[0024] Figure 2 The first type of probe (top) shows probes that can directly bind to the target nucleic acid. In the figure below, the probe has bound to the target nucleic acid, shown as a blue curve. In this and subsequent figures, reporter probes include six sites (indicated by colored circles) where they hybridize with the labeled oligonucleotide. Because the probe contains sites where it can hybridize with the labeled oligonucleotide, it is also called a reporter probe.
[0025] Figure 3 This illustrates a first type of dual-probe composition of the present invention. Here, the first-type probe binds directly to the target nucleic acid, and the first-type capture probe binds directly to the target nucleic acid. The capture probe may include at least one affinity reagent, shown as an asterisk. The target nucleic acid in the sample is shown as a blue curve.
[0026] Figure 4 The top section shows a type II probe (or reporter probe) that can indirectly bind to the target nucleic acid in the sample. Here, the probe's target is the intermediate oligonucleotide shown in green, which then binds to the target nucleic acid in the sample (shown as the blue curve in the figure below). The intermediate oligonucleotide can be considered the probe as defined in this paper because it contains the nucleic acid backbone and is capable of binding to the target nucleic acid.
[0027] Figure 5: This shows a second type of dual-probe composition of the present invention. Here, the second type probe binds indirectly to the target nucleic acid in the sample (via an intermediate oligonucleotide shown in green), and the second type capture probe binds indirectly to the target nucleic acid in the sample (via another intermediate oligonucleotide shown in orange). The capture probe may include at least one affinity reagent, which is shown as an asterisk.
[0028] Figure 6 : This indicates that the signal oligonucleotide binds indirectly to the target nucleic acid in the sample (in a second-type probe). Figure 4 The release of the signal oligonucleotide (as described in the description). The location of the cleavable motif within the probe (or in the reporting probe) affects the type of material contained in the released signal oligonucleotide.
[0029] Figure 7 This section shows three types of probes used for protein detection. In the upper configuration, the probe contains a nucleic acid linked to a protein-binding domain. In this configuration, a cleavable motif (e.g., a cleavable linker, not shown) may be included between the nucleic acid and the protein-binding domain or within the nucleic acid itself. In the intermediate configuration, the protein-binding domain is linked to the nucleic acid, and the probe hybridizes with the nucleic acid. Before or after the target-binding domain binds to the protein target, the probe (containing the target-binding domain and the nucleic acid linked to the protein-binding domain (shown in green)) can be bound by the probe (e.g., in...). Figure 8 (As shown in the image). Cleavable motifs may be included in any one or both of the backbone or nucleic acids linked to protein-binding domains. Figure 2 and 4 The first or second type of probe shown can be used in this configuration to detect proteins. In the lower configuration, a protein-binding domain is attached to a nucleic acid, and an intermediate oligonucleotide (shown in red) hybridizes with both the probe and the nucleic acid attached to the protein-binding domain. Figure 2 and 4 The first or second type of probe shown can be used for this configuration to detect proteins.
[0030] Figure 8 :show Figure 7 The middle and lower portions of the probe. The top two images show the probe before and after protein binding. The next image shows the probe after its cleavable motif has been cleaved, in which the cleavable motif is located between the nucleic acid and the target-binding domain. Once the nucleic acid has been released, it can be considered a signal oligonucleotide. In the lower image, the signal oligonucleotide (the released nucleic acid of the probe) is reported to have bound to the probe (e.g., in...). Figure 2 and 4 As shown in the image).
[0031] Figure 9 : Display signal oligonucleotide self Figure 7 The intermediate configuration of the probe shown in the image and Figure 8 Probe release. The location of the cleavable motif within the probe (or in the reporting probe) affects the type of material contained in the released signal oligonucleotide.
[0032] Figure 10 : Steps in the method of the present invention for detecting signal oligonucleotides in a target region (ROI).
[0033] Figure 11 The diagram illustrates the steps of the method of the present invention, wherein the target region is located on a first sequential slice of a tissue sample and a probe is applied to a second sequential slice of the tissue sample. A signaling oligonucleotide is released from and collected from the probe that binds to the target in the first target region of the second sequential slice. Then, the signaling oligonucleotide is released from and collected from the probe that binds to the target in the second (up to the nth) target region of the second sequential slice.
[0034] Figure 12 This demonstrates multiplexing detection of multiple target nucleic acids and / or proteins from the first target region, followed by multiplexing detection of multiple target nucleic acids and / or proteins from the second target region.
[0035] Figure 13 This describes the steps in the method of the present invention. The method shown herein may be referred to as "nCounter® Digital Multiplexed Immunohistochemistry (IHC)".
[0036] Figure 14 The nCounter® Digital Multiplexed IHC (upper part) demonstrates that, compared to a standard TSA-based multiplexed IHC (lower part), it simplifies workflows and provides more multiplexed flowcharts.
[0037] Figure 15 The image shows a photograph (top) of the digital mirror device (DMD) attached to the Ti-E microscope and a bright-field image (bottom) of an FFPE tissue section. Light illumination (white dots) on the FFPE tissue (bright-field image) reveals multiple regions of interest (ROIs) approximately ~10-20 μm in size (i.e., single-cell size).
[0038] Figure 16This section describes the components and optical path relevant to the invention when the method includes the use of a digital mirror device (DMD). The wide field of view of the DMD is used to focus illumination onto the sample. An LED provides sufficient illumination to immediately excite the entire field of view, and single-cell illumination is used such that ~80-600 DMD pixels illuminate cells with a diameter of 10 μm. A normal-grade DMD will provide sufficient single-cell resolution. DS: dichroic mirror, FW: filter wheel, and DMD: digital mirror device.
[0039] Figure 17 This section describes the components and optical paths relevant to the invention when the method includes the use of a laser scanning device (e.g., a confocal scanning device). In a confocal scanning structure, a galvo-mirror guides the light. This method requires an inexpensive 405 nm laser. DS: dichroic mirror, FW: filter wheel, and MM: motorized mirror.
[0040] Figure 18 : Micrographs showing the overall histological morphology of the established tonsil samples, initially imaged using dual-color fluorescence imaging with Ki-67 (a marker of cell proliferation, shown in green) and CD3 (an immune cell marker, shown in red). 12 regions (including Figure 19 The four enlarged areas are defined by white boxes.
[0041] Figure 19 :for Figure 18 The graph shows the nCounter® data counts of Ki-67 and CD3 in four regions. The images were obtained from serial slices (to allow for examination of various additional controls). Typically, samples are imaged with fluorescent antibodies and then digitally counted (after UV exposure) using the same slides. Analysis of multiple targets in 12 regions (including the four shown here) reveals different localization profiles of Ki-67 and CD3. A magnified view of the four regions is shown below the graph.
[0042] Figure 20 : Display from Figure 18 The image shows an exemplary count of 30-way multiplexed oligoantibody mixtures across 12 target regions (ROIs) in a tonsil sample. Data were obtained from serial slices (to allow for examination of various additional controls).
[0043] Figure 21 : A micrograph showing the overall histological morphology of T cells in a lymph node melanoma sample, initially imaged using tricolor fluorescence imaging of CD3 (shown in red), CD8 (shown in green), and DAPI (shown in blue). White circles are 25 µm in diameter and enclose three cells.
[0044] Figure 22Displays nCounter® data on CD3 conjugate release from FFPE lymph node tissue sections (5 μm thick) as a function of UV irradiation area (100 μm-1 mm in diameter). Field aperture size is shown below the graph.
[0045] Figure 23 : Showing the effect as a function of UV irradiation area (diameter 100 μm-1 mm), from FFPE lymph node tissue sections (5 μm thick) and from [other sources]. Figure 21 and 22 The nCounter® data for CD45 conjugate release from the same experiment are shown in the figure.
[0046] Figure 24 : Showing the effect as a function of UV irradiation area (diameter 100 μm-1 mm), from FFPE lymph node tissue sections (5 μm thick) and from [other sources]. Figure 21 and 23 The nCounter® data for the release of PD1 conjugates from the same experiment are shown in the figure.
[0047] Figure 25 The left image shows a tissue microarray (TMA) of breast tumor tissue containing varying levels of Her2 protein, as shown in the micrograph (middle image), which was identified by IHC staining for Her2 fluorescence. The right image shows a magnified view of a single region from the middle image.
[0048] Figure 26 Displays the relationship between nCounter® count data for 48 representative regions and Her2 status (ASCO-CAP criterion).
[0049] Figure 27 : Drawing about Figure 26 The nCounter® counts of the 48 mentioned regions are summed with the pixel intensity (x 10). 3 The relationship between ).
[0050] Figure 28 To establish a general histological micrograph of the melanoma sample, it was initially imaged using dual-color fluorescence imaging with CD3 (shown in red) and DAPI (shown in blue). Ten exemplary regions are defined by white boxes.
[0051] Figure 29 : Display from Figure 28 The example count of the 30-plex oligoantibody mixture on 10 target regions (ROIs) of the sample is shown in the image.
[0052] Figure 30A and Figure 30B: A micrograph showing a single cell (shown in blue) in a tonsil tissue sample (shown in green) irradiated with UV light using a digital microscopy (DMD) apparatus.
[0053] Figures 31A-31D: Micrographs showing single cells (shown in bright white) in tonsil tissue samples irradiated with UV light using a digital microscopy (DMD) apparatus. Figure 31B The single cell marked in Figure 31A is highlighted. Figure 31D The single cell marked in Figure 31C is highlighted.
[0054] Figure 32 This section describes the steps involved in spatially resolved FFPE tissue protein assays. These steps are similar to those in nucleic acid assays, except that the sample binds to a probe containing a nucleic acid target-binding domain rather than an antibody.
[0055] Figure 33 : Show the steps in spatially resolved FFPE tissue protein assay.
[0056] Figure 34 This displays data from one implementation where an entire tissue or sample is irradiated, for example, with a standard UV gel box to release signal oligonucleotides previously attached to a probe.
[0057] Figure 35 : Show an implementation where a portion of a tissue or sample is irradiated with a microscope, i.e., UV lysis (time titration experiment) is performed under a microscope.
[0058] Figure 36 : Show an implementation where a portion of a tissue or sample is irradiated, for example, under a microscope, i.e., UV lysis is performed under a microscope (irradiation area titration experiment).
[0059] Figure 37 : Show an implementation where a portion of a tissue or sample is irradiated, for example, with a microscope, i.e., UV lysis is performed under a microscope (irradiation area titration experiment - multiple targets).
[0060] Figure 38 : Shows an implementation in which biomarker expression in a target region of a tissue (e.g., a breast cancer sample) is first identified, and then the target region is irradiated (e.g., with UV) to release signaling oligonucleotides from the probe.
[0061] Figure 39 This displays an implementation where tissue packages are embedded in a flow cell. It also displays data for multiple fractions. (Similar to...) Figure 38 Similar to the data, this section pre-identifies the expression of fluorescent markers in the target area. Photographs and schematic diagrams illustrating the device structure are also shown.
[0062] Figure 40 This section shows an implementation where tissue packages are embedded in a flow cell with small holes. Photographs and schematic diagrams illustrating the device structure are also shown.
[0063] Figures 41A-41C The implementation using a flow cell with small orifices demonstrates a significant improvement in signal-to-noise ratio compared to self-organized collection of the eluent across the entire surface. Photographs and schematic diagrams illustrating the device structure are also shown.
[0064] Figures 42A-42C : Data shown in implementations using flow cells with small orifices (12 or 96-orifice style).
[0065] Figure 43A B: Shows a comparison of the background signal from the flow cell in which whole tissue elution was performed. Figure 43A ) and the background signal from the flow cell where elution occurs directly above the target region ( Figure 43B (Data).
[0066] Figure 44 This is a schematic diagram illustrating eluent collection in a multi-target region aspiration implementation scheme with open surfaces. A multi-tube array for eluent aspiration / dispensing is shown here, selected using a rotary valve.
[0067] Figure 45 Includes photographs and diagrams showing one embodiment, in which the eluent is collected via a capillary (micro-aspirator).
[0068] Figure 46A And B: Showing from Figure 45 Data from the implementation scheme, wherein the eluent is collected via a capillary (micro-suction device).
[0069] Figure 47 This is a schematic diagram illustrating an implementation scheme with open surfaces for aspiration of multiple target areas or for eluent collection of a single target area. It shows a multi-tube array using aspiration and capillary action for aspiration / dispensing, as well as a single tube / absorption tube with a fixed position.
[0070] Figure 48 : A schematic diagram illustrating the illumination and collection of fluid by combining a capillary tube and a lens.
[0071] Figure 49 : A schematic diagram illustrating the steps in an implementation scheme for spatially resolved FFPE tissue assays containing a 96-well grid.
[0072] Figure 50 : Displays protein expression data obtained from single or two cells using the methods and apparatus described herein.
[0073] Figure 51 : Identify target regions located on sequential slices of a single tumor sample.
[0074] Figure 52 The results show the counts obtained for 6 of the 9 RNA probes included in the assay of Example 16.
[0075] Figure 53 :show Figure 52 The average and standard deviation of the counts are displayed.
[0076] Figure 54 Displays RNA expression and protein data for probes that simultaneously hybridize with nCounter® molecular barcodes and are digitally counted using the nCounter® system from NanoString Technologies®.
[0077] Figure 55 : Shows RNA expression data obtained from single-stranded DNA probes and some double-stranded DNA probes.
[0078] Figure 56 : Shows RNA expression data of probes hybridized in the presence of salmon sperm DNA.
[0079] Figure 57 This shows RNA expression data from probes specific to PSA (prostate-specific antigen).
[0080] Figure 58 This indicates increased probe specificity at non-standard sub-nM concentrations. Invention Details This invention is partly based on probes, compositions, methods, and kits for the simultaneous, multiplexed detection and quantification of protein and / or nucleic acid expression in user-defined tissue regions, user-defined cells, and / or user-defined intracellular subcellular structures.
[0082] This invention provides a comparison of the identity and abundance of target proteins and / or target nucleic acids present in a first target region (e.g., tissue type, cell type (including normal and abnormal cells), and subcellular structures within the cell) with the identity and abundance of target proteins and / or target nucleic acids present in a second target region. There is no predefined upper limit to the number of target regions and the comparisons that can be made; the upper limit is related to the size of the target regions relative to the sample size. As an example, when a single cell represents a target region, then a section may have hundreds to thousands of target regions; however, if a tissue section includes only two cell types, then the section may have only two target regions (each including only one cell type).
[0083] This invention provides a higher degree of multiplexing than standard immunohistochemistry or in situ hybridization methods. Standard immunohistochemistry allows for the simultaneous detection of up to 6-10 protein targets, more typically 3-4. Similarly, in situ hybridization is limited to the simultaneous detection of fewer than 10 nucleic acid targets. This invention provides the ability to detect large combinations of nucleic acid and / or protein targets in customized sample regions. This invention provides increased target measurement, reliability, and consistency through digital quantification, thereby enabling comparison of results across multiple centers.
[0084] The probes of this invention may have a nucleic acid backbone (single-stranded DNA or RNA) having defined positions capable of hybridizing (non-covalently binding) with at least one labeled oligonucleotide. See also Figure 1 Such probes (which have defined positions capable of hybridizing with at least one labeled oligonucleotide) are also referred to herein as reporter probes. The number of positions on a reporter probe backbone ranges from 1 to 100 or more. In embodiments, the number of positions ranges from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 to 15, 20, 30, 40 or 50 or any range therebetween. Indeed, there is no limit to the number of positions on the backbone (for detecting target nucleic acids and / or for detecting target proteins), as engineering such a backbone is entirely within the capabilities of a technician. The number of target nucleic acids and / or proteins that can be detected by the probe set depends on the number of positions included in the probe backbone.
[0085] The labeled oligonucleotides used in this article refer to RNA fragments that include detectable labels or DNA oligonucleotides that include detectable labels.
[0086] The nucleic acid backbone position may hybridize (non-covalently) with at least one labeled oligonucleotide. Alternatively, the position may hybridize with at least one oligonucleotide lacking a detectable label. Each position may hybridize with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21-100 labeled (or unlabeled) oligonucleotides or more. The number of labeled oligonucleotides hybridizing with each position depends on the position length and the size of the oligonucleotides. The position length may be between about 300 and about 1500 nucleotides. The length of the labeled (or unlabeled) oligonucleotide varies from about 20 to about 1500 nucleotides. In an embodiment, the length of the labeled (or unlabeled) oligonucleotide varies from about 800 to about 1300 ribonucleotides. In other embodiments, the length of the labeled (or unlabeled) oligonucleotides varies from about 20 to about 55 deoxyribonucleotides, and these oligonucleotides are designed to have a melting / hybridization temperature of about 65 to about 85°C, for example, about 80°C. For example, a position of about 1100 nucleotides in length can hybridize with about 25 to about 45 oligonucleotides, each oligonucleotide being about 45 to about 25 deoxyribonucleotides in length. In one embodiment, each position hybridizes with about 34 labeled oligonucleotides of about 33 deoxyribonucleotides in length. The labeled oligonucleotides are preferably single-stranded DNA.
[0087] Each labeled oligonucleotide can be labeled with one or more detectable label monomers. The label can be located at the end of the oligonucleotide, at a site within the oligonucleotide, or a combination thereof. The oligonucleotide may contain nucleotides with amine modifications, which enable the detectable label to be coupled to the nucleotide.
[0088] The labeled oligonucleotides of this invention can be labeled using any of a variety of labeling monomers, such as fulorochromes, quantum dots, dyes, enzymes, nanoparticles, chemiluminescent markers, biotin, or other monomers known in the art that can be detected directly (e.g., by light emission) or indirectly (e.g., by binding to a fluorescently labeled antibody). A preferred example of a label that can be used by this invention is a fluorophore. Several fluorophores can be used as labeling monomers for labeled nucleotides, including but not limited to GFP-related proteins, anthocyanin dyes, fluorescein, rhodamine, and ALEXA Flour. TM Texas Red, FAM, JOE, TAMRA, and ROX are among the several known fluorophores, and more are being produced, covering the entire spectrum.
[0089] The marker associated with each position (via hybridization of the oligonucleotide with the position) can be spatially separated and spectrally resolved with the marker at the preceding or following position. This series of ordered, spatially separable, and spectrally resolved markers of the probe is referred to herein as a barcode or tag code. Barcodes or tag codes enable the identification of target nucleic acids or proteins that have been bound by a specific probe.
[0090] The labeled oligonucleotides hybridize to their sites in a standard hybridization reaction, such as at 65°C and 5 x SSPE, which allows for the self-assembly of reporter probes or other probes. Probes using longer RNA molecules as labeled oligonucleotides (e.g., as described in US2003 / 0013091) must be pre-assembled at the manufacturing site, rather than by the end user, at higher temperatures to avoid cross-linking multiple backbones via the longer RNA molecules. Purification is performed after the pre-assembly step to remove excess unhybridized RNA molecules, which increase background. The use of short, single-stranded labeled oligonucleotides (e.g., containing deoxyribonucleotides) greatly simplifies probe fabrication and reduces the costs associated with its manufacture.
[0091] In the implementation scheme, the probe is provided to the sample at a concentration generally lower than that used for immunohistochemistry (IHC) or in situ hybridization (ISH). Alternatively, the concentration may be significantly lower than that used for IHC or ISH. For example, the probe concentration may be as low as 1 / 2, 1 / 5, 1 / 10, 1 / 20, 1 / 25, 1 / 30, 1 / 50, 1 / 60, 1 / 70, 1 / 80, 1 / 90, 1 / 100, 1 / 200, 1 / 300, 1 / 400, 1 / 500, 1 / 600, 1 / 700, 1 / 800, 1 / 900, 1 / 1000, 1 / 2000 or lower and any number in between. In the implementation scheme, the probe is provided at concentrations of 100 nM, 70 nM, 60 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 0.9 nM, 0.8 nM, 0.7 nM, 0.6 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.2 nM, 0.1 nM, 0.09 nM, 0.08 nM, 0.07 nM, 0.06 nM, 0.05 nM, 0.04 nM, 0.03 nM, 0.02 nM, 0.01 nM and lower, and any concentrations in between.
[0092] The probe can be detected and quantified using commercially available columns, software, and systems (such as the nCounter® system using the nCounter® Cartridge).
[0093] Background noise during protein detection can be reduced by performing negative purification of the intact probe molecule. This can be achieved by affinity purification with an antibody or photolyzable linker after collecting the eluent from the target region. Typically, the released signal oligonucleotide does not detach from solution. Protein-G or-O mechanisms in the pipette tip, tube, or plate can be used for this step. Such devices and reagents are commercially available.
[0094] Background noise during nucleic acid detection can be reduced by performing negative purification of the intact probe molecule. This can be achieved by affinity purification of the target-binding domain or photolyzable linker after collecting the eluent from the target region. Normally, the released signal oligonucleotide does not detach from solution. To facilitate negative purification, a universal purification sequence can be included in the probe, for example, in the target-binding domain.
[0095] Figure 1 Shown are two exemplary probes comprising a single-stranded nucleic acid backbone and a target-binding domain shown in red. The upper probe comprises a labeled RNA fragment that hybridizes to a position in the backbone, while the lower probe comprises a labeled DNA oligonucleotide that hybridizes to a position in the nucleic acid backbone. Figure 1 The colors shown in this disclosure and elsewhere are not limiting; other color markings and other detectable markings known in the art may be used for the probes of this invention.
[0096] The probes of this invention can be used to detect target nucleic acids. Figure 2 and 4 This aspect is explained. Such a probe includes at least a backbone and a target nucleic acid binding region. The length of the target nucleic acid binding region is preferably at least 15 nucleotides, and more preferably at least 20 nucleotides. In specific embodiments, the length of the target nucleic acid binding region is about 10-500, 20-400, 25, 30-300, 35, 40-200, or 50-100 nucleotides. Probes and methods for binding and identifying target nucleic acids have been described, for example, in US2003 / 0013091, US2007 / 0166708, US2010 / 0015607, US2010 / 0261026, US2010 / 0262374, US2010 / 0112710, US2010 / 0047924, and US2014 / 0371088, each of which is hereby referred to in its entirety.
[0097] Protein targets can be complete proteins, various polypeptides, or peptides.
[0098] The probes of this invention can be used to directly hybridize with target nucleic acids. Figure 2 The diagram illustrates the probe (or composition) of this embodiment. The probe includes a target nucleic acid binding domain shown in red. The target nucleic acid is shown as a blue curve. Figure 3The illustrated explanation includes Figure 2 A dual-probe composition comprising a probe and a capture probe. The capture probe contains at least one affinity reagent, shown as an asterisk. At least one affinity moiety is attached to the capture probe by covalent or non-covalent means. Various affinity moieties suitable for purification and / or immobilization are known in the art. Preferably, the affinity moiety is biotin, avidin, or streptavidin. Other affinity tags are specifically recognized by binding couplers and thus facilitate separation and immobilization by affinity binding to the binding couplers, which can be immobilized on a solid support. In these figures, each probe includes six sites for hybridization with a labeled oligonucleotide, each site being identified by a colored circle.
[0099] Any probe of the present invention may contain an affinity portion.
[0100] The probes of this invention can be used to indirectly hybridize with target nucleic acids present in a sample (via an intermediate oligonucleotide). Figure 4 This describes the probe (or composition) of this embodiment. The probe includes a target nucleic acid binding domain, shown in red, which binds to a synthetic oligonucleotide (intermediate oligonucleotide, shown in green), which in turn binds to the target nucleic acid in the biological sample. The intermediate oligonucleotide can be considered the probe as defined herein because it contains a nucleic acid backbone and is capable of binding the target nucleic acid. The target nucleic acid present in the biological sample is shown as a blue curve. Figure 5 The instructions include Figure 4 The invention comprises a dual-probe composition of a probe and a capture probe. In these embodiments, the target nucleic acid binding region of the probe hybridizes with a region of an intermediate oligonucleotide (i.e., a synthetic oligonucleotide) that is different from the target nucleic acid present in the sample. Therefore, the target binding region of the probe is independent of the final target nucleic acid in the sample. This allows for economical and rapid flexibility in assay design, as the target-specific component (present in the sample) is included in an inexpensive and widely available synthetic DNA oligonucleotide instead of a more expensive probe. Such synthetic oligonucleotides are simply designed by including a region that hybridizes with the target nucleic acid present in the sample and a region that hybridizes with the probe. Therefore, by simply replacing the target-specific (synthetic) oligonucleotide portion of the assay, a single set of indirect binding probes can be used to detect an unlimited number of target nucleic acids (present in the sample) in different experiments.
[0101] The probes or probes of the present invention may include regions that allow the release of a signal oligonucleotide upon application of a suitable force. In one non-limiting example, the region is a cleavable motif (e.g., a restriction enzyme cleavage site or a cleavable adapter). The cleavable motif enables the release of the signal oligonucleotide from a self-binding target nucleic acid or target protein, which is then collected and detected. The signal oligonucleotide used herein is either a probe region currently having a site for hybridization with at least one labeled oligonucleotide, or a probe (e.g., a nucleic acid molecule) region that is self-releaseable from the target-binding domain of the probe. The signal oligonucleotide is said to be releasable when it can be separated from the rest of the probe (i.e., cleaved and released). Examples of a cleavable motive include, but are not limited to, photocleavable adapters.
[0102] In the probes of this invention (as described herein), cleavable motifs may be located between the nucleic acid and the target-binding domain, between the backbone and the target-binding domain, or within the backbone. Figure 6 In this context, the non-restrictive option for the location of the cleavable motif can be inferred from the gap within the probe or the gap within the intermediate oligonucleotide.
[0103] The probe of this invention can be used to detect target proteins. Figure 7 The diagram illustrates the probe (or composition) of this embodiment. Such a probe includes at least a backbone and a target protein binding region. In the protein-targeting probes of the present invention, the signal oligonucleotide may be a nucleic acid linked to a protein-binding domain. In these probes, the signal oligonucleotide is targeted and bound by a probe containing a site for hybridization with a labeled oligonucleotide. Such probes are shown... Figure 7 (Middle image). There, the signal oligonucleotide is observed as a green line. The probe can be bound to the protein before or after it binds to the protein (via its protein-binding domain). The signal oligonucleotide does not need to be bound to the probe until it has been released from the target-binding domain (this embodiment is not shown).
[0104] Probe regions capable of binding to target proteins include molecules or assemblies designed to bind to at least one protein target, at least one protein target substitute, or both, and capable of forming a molecular complex comprising a protein probe and a target protein under suitable conditions. Regions capable of binding to target proteins include antibodies, peptides, aptamers, or peptide-like molecules. Antibodies are available from a variety of sources, including but not limited to polyclonal antibodies, monoclonal antibodies, monospecific antibodies, recombinantly expressed antibodies, humanized antibodies, plant antibodies, etc. The terms protein, polypeptide, peptide, and amino acid sequence are used interchangeably herein to refer to polymers of amino acids of any length. Polymers may be linear or branched, may contain modified amino acids, and may be interrupted by non-amino acid or synthetic amino acids. The term also includes amino acid polymers modified, for example, by disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other operation (such as conjugation with a labeled component). The term amino acid as used herein refers to natural and / or non-natural or synthetic amino acids, including but not limited to glycine and both D or L optical isomers, as well as amino acid analogs and peptide mimics. Probes and methods for binding to and identifying target proteins have been described, for example, in US2011 / 0086774, the contents of which are incorporated herein by reference in their entirety.
[0105] In this embodiment, the probe is prepared via a cysteine bioconjugation method, which is stable and preferably site-specific to the heavy chain of the antibody hinge region. This preparation method provides a relatively controllable stoichiometric ratio of labeled oligonucleotides to antibodies. The probe may contain multiple (i.e., more than one, e.g., 2, 3, 4, 5, or more) labeled oligonucleotides / antibodies. Typically, "heavier" probes containing 3 or 4 labeled oligonucleotides / antibodies are significantly less sensitive than antibodies lacking labeled oligonucleotides or "lighter" probes (which contain 1 or 2 labeled oligonucleotides / antibodies).
[0106] Protein-targeting probes and nucleic acid-targeting probes can be used simultaneously, provided that conditions allow for the binding of both protein and nucleic acid targets. Alternatively, when conditions do not allow for the binding of both protein and nucleic acid targets, protein-targeting probes and nucleic acid-targeting probes can be used sequentially.
[0107] A probe set is synonymous with a probe composition. A probe set includes at least one probe, i.e., a target. A probe set preferably includes at least two, such as 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, or more probes. A probe set may include one or more copies of each probe.
[0108] Only the first set of probes can be applied to the sample. Alternatively, a second set (or more) of probes can be applied to the sample later. The first and second sets (or more) can target only nucleic acids, only proteins, or combinations thereof.
[0109] In this invention, two or more targets (i.e., proteins, nucleic acids, or combinations thereof) are detected, and 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 or more targets and any number thereof are detected.
[0110] Probe sets can be predefined based on the cell or tissue type to be targeted. For example, if the tissue is breast cancer, the probe set would include probes targeting proteins associated with breast cancer cells (such as Her2, EGFR, and PR) and / or probes targeting proteins associated with normal breast tissue. Alternatively, the probe set can be predefined based on the developmental state of the cell or tissue to be targeted. Or, the probe set can be predefined based on the subcellular localization of the target, such as the nucleus, cytoplasm, and membrane. For example, antibodies targeting Foxp3, histone H3, or P-S6 label the nucleus; antibodies targeting CD3, CD4, PD-1, or CD45RO label the cytoplasm; and an antibody targeting PD-L1 label the membrane.
[0111] The probe can be chemically synthesized or produced using a vector organism in which the nucleic acid encoding the probe is cloned.
[0112] Any probe or probe set described herein can be used in the methods and kits of this invention.
[0113] For the probes described in this article, the association between the tag code and the target nucleic acid or target protein is not fixed.
[0114] The probes of this invention can be used to detect target nucleic acids or target proteins present in any sample, such as a biological sample. As those skilled in the art will appreciate, the sample may contain any number of substances, including but not limited to: cells (including both primary cells and cultured cell lines) and tissues (including cultured or transplanted tissues). In embodiments, tissue samples (fixed or unfixed) are embedded, serially sectioned, and fixed onto a microscope slide. As is well known, a pair of serial sections will include at least one cell present in both serial sections. Structures and cell types located on the first serial section have similar locations on adjacent serial sections. The sample may be cultured cells or dissociated cells (fixed or unfixed) fixed on a slide.
[0115] In the implementation plan, the tissue sample is a biopsied tumor or a portion thereof, i.e., a clinically relevant tissue sample. For example, the tumor may be from breast cancer. The sample may be a resected lymph node.
[0116] Samples can be obtained from almost any organism, including multicellular organisms such as plants, fungi, and animals. Preferably, samples are obtained from animals such as mammals. Human samples are particularly preferred.
[0117] In some embodiments, the probes, compositions, methods, and kits described herein are used to diagnose a disease. The term "diagnosis" as used herein includes predicting or diagnosing a disease, determining susceptibility to a disease, monitoring treatment for a disease, diagnosing treatment response to a disease and its prognosis, disease progression, and response to disease-specific treatments. For example, a tissue sample can be measured according to any of the probes, methods, or kits described herein to determine the presence and / or quantity (relative to a disease-free state) of markers of disease or malignant cell types in the sample, thereby diagnosing or staging a disease or cancer.
[0118] Typically, the sample attached to the slide can first be imaged using fluorescence (e.g., fluorescent antibodies or fluorescent dyes (e.g., DAPI)) to identify morphology, target regions, target cell types, and single cells, and then the expression of proteins and / or nucleic acids can be digitally counted from the sample on the same slide.
[0119] The compositions and kits of the present invention may include probes and other reagents, such as buffers and other reagents known in the art, to promote the binding of proteins and / or nucleic acids in a sample, i.e., to perform a hybridization reaction.
[0120] The kit will also include instructions for using the kit components, including but not limited to information necessary for hybridizing the labeled oligonucleotide with the probe, hybridizing the probe with the target-specific oligonucleotide, hybridizing the target-specific oligonucleotide with the target nucleic acid, and / or hybridizing the probe with the target protein.
[0121] The following describes exemplary protocols for detecting target nucleic acids and / or target proteins, and as in Figure 10-14 As shown (at the top).
[0122] Prepare cell (live or fixed) or tissue sections (e.g., formalin-fixed paraffin-embedded (FFPE)) prepared in accordance with multiplexed immunohistochemistry and / or nucleic acid in situ hybridization methods, and fix them on glass slides or suitable solid supports. Maintain an entrance to the surface of the cells or tissue sections to allow fluid exchange, which can be achieved using a fluid chamber reagent exchange system (e.g., Grace). TMBio-Labs (Bend OR) is used to achieve this. The target region (ROI) is determined on sequential slices of the sample to be provided or on adjacent sequential slices. In the first case, a complete "macroscopic feature" imaging method is performed on the target cells / tissue, such as DAPI staining, membrane staining, mitochondrial staining, specific epitope staining, and specific transcript staining, to determine the overall macroscopic features of the target cells / tissue. Alternatively, the target region (ROI) is determined on sequential slices adjacent to the sequential slice of the sample to be provided, where the first sequential slice (… Figure 11 and 12 Slice #1 in the image is used to perform full "macro-feature" imaging (as described above). This imaging will typically identify target regions on adjacent consecutive slices. Figure 10 The red line in Figure B and Figure 11 and 12 The green ovals and green triangles in slice #2 indicate that the signal oligonucleotide will be released from the probe when appropriate and directional forces are applied. Serial slices can be approximately 5 μm-15 μm apart.
[0123] Figure 13 and Figure 14 The upper part also illustrates the steps of the present invention. Figure 13 The steps shown include the following: (1) Procedure: Tissue mounted on an FFPE slide is incubated with a primary antibody mixture conjugated with DNA oligomers via photolyzable linkers and a limited number of visible wavelength imaging reagents. (2) Observation: Target regions (ROIs) are identified using visible light-based imaging reagents in a low-path multiplexing manner to establish the overall “structure” of the tumor slice (e.g., imagenuclei and / or using one or two key tumor biomarkers). (3) Profile: ROIs are selected for high-resolution multiplexed profile analysis, and oligomers in the selected regions are released upon exposure to UV light. (4) Plating: The free photolyzed oligomers are then collected, for example, via a microcapillary-based “pipette” and stored in the wells of a microplate for subsequent quantification. (5) Digital counting: During the digital counting step, photolyzed oligomers from spatially resolved ROIs in the microplate are hybridized with 4-color 6-dot optical barcodes, enabling the use of standard NanoStringn Counter® reading instruments (such as SPRINT, Flex and MAX) to count up to ~1 million protein targets in a single ROI (distributed across up to 800 multiplexed markers).
[0124] The target region can be a tissue type, cell type, cell, or subcellular structure within a cell that exists in the sample.
[0125] Compositions comprising a probe set are applied to serial sections, each probe containing a signal-releasing oligonucleotide. This probe set may include probes targeting proteins, nucleic acids, or both. The composition may include capture probes. When the probes bind indirectly to the target (protein and / or nucleic acid), the applied composition includes an intermediate oligonucleotide. The composition will include other reagents known in the art to facilitate the binding of proteins and / or nucleic acids in the sample.
[0126] Perform a blocking step before and / or after applying the composition.
[0127] For probes including photolytically cleavable joints, a solid support (e.g., a microscope slide) is placed in a microscope capable of providing excitation light at a wavelength that can cleave the photolytically cleavable joint. The first target region is then excited with light. Figure 10 The red line in Figure B and Figure 11 and 12 ROI in i This process cleaves the photolytic linker, releasing the signal oligonucleotide. For example, in... Figure 6 and 9 As illustrated in the diagram, the signal oligonucleotide includes at least a probe region currently having a site for binding to at least one labeled oligonucleotide, or a nucleic acid from a probe that is reported to bind to or be able to bind to. By directing excitation light only to the ROIi, only the signal oligonucleotide is released from the probe within the ROIi, rather than from probes located outside the ROIi, thus preserving its signal oligonucleotide. Therefore, only the signal oligonucleotide of the probe that binds to the target within the ROIi is collected, thereby allowing the detection of the identity and quantity of targets (proteins and / or nucleic acids) located within the ROIi.
[0128] Wash the surface of the slice with a small amount of buffer (~5-30 μl), and collect the eluent (containing the released signal oligonucleotide) into the first sample container (in Figure 12 (Shown as sample "i" in the image). The surface of the slice was also rinsed to remove any released signal oligonucleotides missed in the eluent.
[0129] Excite the second target region with light ( Figure 11 and 12 ROI in j This process cleaves the photolyzable linker and releases the signal oligonucleotide from the second target region. Again, by directing excitation light only to ROIj, the signal oligonucleotide is released only from probes within ROIj, not from probes located outside ROIj that retain their signal oligonucleotides. Therefore, only the signal oligonucleotides of probes that bind to targets within ROIj are collected, allowing for the detection of the identity and quantity of targets (proteins and / or nucleic acids) located within ROIj.
[0130] Wash the surface of the slice with a small amount of buffer (~5-30 μl), and collect the eluent (containing the released signal oligonucleotide) into the first sample tube (in Figure 12 (Shown as sample "j" in the image). The surface of the slice was also rinsed to remove any released signal oligonucleotides missed in the eluent.
[0131] Repeat the activation, washing, and rinsing steps until samples are collected from all target areas (up to ROI). n Signal oligonucleotides.
[0132] Further advantages, features, and embodiments of the invention are described in the accompanying appendix. Various methods and apparatuses for collecting signal oligonucleotides and various ways of providing force are shown as examples. Furthermore, the appendix provides unexpected improvements over other embodiments of the invention derived from certain embodiments. The data shown confirm an improvement in signal-to-noise ratio of approximately 7 to approximately 200 times.
[0133] The examination can be performed using any type of microscope device or system known in the art. The device or system may include a digital microscope device (DMD, see below). Figure 15 and 16 The wide field of view illumination provided together offers advantages including reduced cost, as the DMD and controller can also drive the LED (its photolysis probe) with virtually no additional cost; ease of implementation; allow for feature sizes as small as ~1 mm (which would include 10-40 mm cells); and adaptability to consumer electronics (like projectors). The device or system may include laser scanning devices, such as confocal ones, see [link to relevant documentation]. Figure 16 Its advantage is that smaller morphological features can be irradiated and imaged; however, these devices involve additional costs.
[0134] Polymerase reactions, reverse transcriptase reactions, hybridization with oligonucleotide microarrays, mass spectrometry, hybridization with fluorescent molecular beacons, sequencing reactions, or nCounter® molecular barcoding are used to identify multiple target proteins and / or target nucleic acids present in each target region of the sample in each elution sample. This is achieved using NanoString Technologies as described in US2003 / 0013091, US2007 / 0166708, US2010 / 0015607, US2010 / 0261026, US2010 / 0262374, US2010 / 0112710, US2010 / 0047924, US2014 / 0371088, and US2011 / 0086774. ® nCounter ® Systems and methods provided as preferred means for identifying target proteins and / or target nucleic acids. (From NanoString Technologies)® nCounter ® The system and methods enable the simultaneous multiplexing of identification of multiple (800 or more) different target proteins and / or target nucleic acids.
[0135] The identity and abundance of target proteins and / or target nucleic acids present in a first target region (e.g., tissue type, cell type (including normal and abnormal cells), and subcellular structures within the cell) can be compared with the identity and abundance of target proteins and / or target nucleic acids present in a second or more target regions.
[0136] This invention provides multiplexed detection and comparison of up to 800 target proteins from discrete regions within tumors and their adjacent normal tissues, thus enabling a systematic exploration of tumors and their microenvironment.
[0137] This invention can be used in ongoing clinical studies to elucidate new responses to immunotherapy and other targeted therapies.
[0138] This invention also enables the discovery of immune biomarkers in tumors (e.g.), which can be used to develop companion diagnostics.
[0139] Immunohistochemistry is a powerful technique for analyzing protein expression and localization in FFPE tissue sections. However, it faces many challenges, including a lack of dynamic range, difficulty in quantification, and a labor-intensive workflow with very limited multiplexing. This paper discloses a novel platform based on nCounter® barcode technology, which enables highly multiplexed (up to 800 multiplexes) assays (i.e., nCounter). ® Spatial-resolved digital characterization of proteins is performed using a Digital Multiplexed Immunohistochemistry (IHC) assay. This assay relies on antibodies coupled to photolyzable oligonucleotide tags released from self-organized discrete regions using UV (e.g., ~365 nm) exposure through an objective lens. The cleaved tags are quantified in an nCounter® assay, and the counts are mapped back to the tissue location to obtain a spatial-resolved digital profile of protein abundance. Protein detection can be performed together with or separately from nucleic acid detection assays using nucleic acid probes containing photolyzable oligonucleotide tags. Therefore, this invention provides spatial-resolved digital profiles of protein abundance, spatial-resolved digital profiles of protein and nucleic acid abundance, or spatial-resolved digital profiles of nucleic acid abundance.
[0140] The advantages of the assay include, but are not limited to: high sensitivity (e.g., ~1-4 cells), fully digital counting, large dynamic range (>10⁵), high multiplexing (e.g., 30 targets and expandable to 800 targets without instrument changes), simple workflow, compatibility with FFPE, no secondary antibodies (for protein detection) or amplification reagents, and potential for clinical assays.
[0141] As used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include the plural references, unless the context clearly indicates otherwise.
[0142] Unless specifically stated or obvious from the context, the term “or” as used herein should be understood as inclusive and encompasses both “or” and “and”.
[0143] Unless specifically specified or obvious from the context, the term "about" as used herein should be understood as falling within the normal permissible range in the field, such as within two standard deviations of the mean. "About" can be understood as falling within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the specified value. Unless the context clearly indicates otherwise, all numerical values provided herein are modified by the term "about".
[0144] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. While other probes, compositions, methods, and kits similar or equivalent to those described herein may be used to practice this invention, preferred materials and methods are described herein. It should be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. Example
[0145] Example 1: This invention provides "barcode potential" to quantify multiplexed targets in FFPE tissue sections. Intratumoral heterogeneity has become a key challenge in implementing targeted therapies. Historically, immunohistochemistry (IHC) has been used to evaluate the spatial heterogeneity of proteins; however, it is difficult to quantify protein abundance with high multiplexing and a wide dynamic range.
[0146] In this embodiment, proteins in formalin-fixed paraffin-embedded (FFPE) tissue sections are labeled with antibody-containing probes including photolyzable linkers and fluorescent barcodes. The probes (within a user-defined region of interest (ROI) of the FFPE tissue section) are then exposed to focused UV light, thereby releasing signal oligonucleotides (containing fluorescent barcodes) from the ROI. The released signal oligonucleotides are washed away from the FFPE sample and collected. The fluorescent barcodes from the released signal oligonucleotides are then identified and digitally counted using an nCounter® system from NanoString Technologies® to quantify the abundance of each target protein in a user-defined spatial region of the tissue section. After releasing and collecting the signal oligonucleotides from the first ROI, focused UV light is exposed to a second user-defined ROI of the FFPE tissue section, thereby releasing signal oligonucleotides from the second ROI. In this non-limiting embodiment, a high linearity (0.97) was observed between the observed counts and the UV-irradiated area. <R 2 <0.99), and has a detection spatial resolution of approximately 100 μm x 100 μm or approximately 100 cells. Unexpectedly, the present invention provides "barcode potential" to quantify up to 800 targets in a single FFPE tissue slice with a dynamic range of 5.5 log (base 10).
[0147] Example 2: This invention provides a practical and feasible method for quantifying protein expression without signal amplification and for achieving higher-order target antigen multiplexing in FFPE tissue sections. Quantitative multiplexed immunohistochemistry has become a highly attractive area of research in oncology due to its unique ability to identify spatiotemporal tissue and interdependencies, and further to determine how checkpoint blockade affects the tumor microenvironment. This example describes a one-step, amplification-free staining method using a primary antibody labeled with a photolytically cleavable oligomer that interacts with the target antigen within FFPE tissue sections. Ultraviolet (UV) light irradiation releases the oligomer from the antibody, followed by eluent collection, quantification, and digital counting corresponding to antigen abundance.
[0148] First, various conjugation methods were studied, and a cysteine bioconjugation method was established. This method is stable, site-specific mainly for the heavy chain in the hinge region, and relatively controllable in terms of the stoichiometric ratio of oligonucleotides to antibodies.
[0149] Next, linear regression analysis was performed to determine the relationship between UV-induced cleavage area and measured numerical protein counts, from which a high linearity (0.97) was observed. <R 2 <0.99), confirming the underlying mechanism / prerequisite associated with this multiplexing protein counting method in FFPE tissues.
[0150] To determine the effect of conjugated oligonucleotides on antibody-antigen interactions, the performance of labeled oligonucleotide-conjugated antibodies versus unmodified antibodies in FFPE tissue sections under identical conditions was compared in terms of sensitivity, specificity, and signal intensity. Antibodies targeting antigens located in the nucleus, cytoplasm, or membrane were selected to determine the relationship between antibody performance and the subcellular location of the target antigen. Selected antibodies targeted Foxp3, histone H3, P-S6 (nuclear antigen), CD3, CD4, PD-1, CD45RO (cytoplasmic antigen), and PD-L1 (membrane antigen). In terms of sensitivity, "heavier" oligonucleotide-conjugated antibodies (with 3 or 4 labeled oligonucleotides / antibody) were generally found to be significantly less sensitive compared to unconjugated antibodies or "lighter" oligonucleotide-conjugated antibodies (with 1 or 2 labeled oligonucleotides / antibody). No significant differences were observed between unconjugated and "lighter" oligonucleotide-conjugated antibodies in terms of sensitivity, specificity, or intensity across nuclear, cytoplasmic, and membrane target antigens.
[0151] This invention provides a highly multiplexed protein profiling analysis that uses a practical and feasible method to measure absolute protein expression levels to comprehensively define the tumor immune landscape before and during immunotherapy intervention.
[0152] Example 3: This invention provides spatially resolved multiplexed protein detection in FFPE tissues. method Antibodies – Antibodies used in this example and Examples 4-6 may include: “Target (clone ID, vendor)”: H3 (D1H2, CST), CD8 (OTI3H6, Origene), CD4 (SP35, Spring Bio), FOXP3 (D2W8E, CST), B7-H3 (D9M2L, CST), S6 (54D2, CST), B7-H4 (D1M8I, CST), Granulase B (OTI4E4, Origene), Ki67 (8D5, CST), PD-1 (Nat105, Cell Marque), CD3 (MRQ-39, Cell Marque), Vista (D1L2G, CST), Her2 (29D8, CST), PR (D8Q2J, CST), ER (SP1, SpringBio), EGFR (D38B1, CST), CD56 (MRQ-42, Cell Marque), PD-L1 (E1L3N, CST), CD45 (2B11 & PD7 / 26, Cell Marque), TIM-3 (D5D5R, CST), and broad-spectrum keratin (Pan Keratin) (C11, CST) and CD45RO (UCHL1, Cell Marque).
[0153] Tonsillar microscopy – 5 μm sections of FFPE tonsil blocks (Amsbio) were mounted on glass slides. IHC was performed using standard protocols. Antigen retrieval was performed using a pressure cooker. Tonsillar sections were stained with CD3 primary antibody MRQ-39 (rabbit mAb, Cell Marque) and Ki-67 primary antibody 8D5 (mouse mAb, CST). Secondary incubation was performed using Alexa 594-labeled goat alpha rabbits (Life Tech) and Alexa 488-labeled goat alpha mice (Life Tech).
[0154] Here, fluorescent antibodies are first used to image the sample attached to the glass slide, and then a digital count of protein expression is performed on the sample.
[0155] The steps to use and Figures 10-14 Similar to those illustrated in the (top) section. UV splitting of the selected ROI enables a full 30-way multiplexed digital profile analysis (nCounter® count).
[0156] result Figure 18Micrographs showing the overall histological morphology of the established tonsil samples, initially imaged using dual-color fluorescence imaging with Ki-67 (a marker of cell proliferation, shown in green) and CD3 (an immune cell marker, shown in red). In 12 regions (including...) Figure 19 Analysis of multiple targets (in four magnified regions) revealed three different profiles of Ki-67 and CD3 localization. Figure 19 show Figure 18 The nCounter® counts for Ki-67 and CD3 in the four regions shown are displayed. Figure 20 Showing from Figure 18 The image shows an exemplary count of 30-way multiplexed oligoantibody mixtures across 12 target regions (ROIs) in a tonsil sample. Data were obtained from serial sections (to allow for examination of various additional controls). As shown, regions of the tissue sample can be categorized based on the intensity and identity of the expressed markers. Exemplary categorizations are shown: “CD3-rich,” “Ki67-rich,” “mixed,” and “connective tissue.”
[0157] These data show that the present invention provides spatially resolved detection of a variety of protein biomarkers (at least 30 here). By increasing the number of protein probes (antibodies) used, up to 800 different protein biomarkers can be detected with similar resolution.
[0158] Example 4: This invention provides multiplexed protein detection from FFPE tissue with near single-cell resolution. method Microscopic examination of melanoma - 5 μm sections of FFPE (Asterand) melanoma (lymph node origin) were mounted on a glass slide. IHC was performed using standard protocol. Antigen retrieval was performed using a pressure cooker.
[0159] Here, fluorescence is first used to image the sample, and then a digital count of protein expression is performed on the sample.
[0160] The steps to use and Figures 10-14 The diagrams in the upper part illustrate those similarities.
[0161] result Figure 21 A micrograph showing the overall histological morphology of T cells in a lymph node melanoma sample, initially imaged using trichromatic fluorescence imaging of CD3 (shown in red), CD8 (shown in green), and DAPI (shown in blue). White circles are 25 µm in diameter and enclose three cells.
[0162] Figure 22The nCounter® data for CD3 conjugate release from FFPE lymph node tissue sections (5 μm thick) are displayed as a function of UV irradiation area (100 μm-1 mm in diameter). The limit of detection (LOD = background count + 2 x standard deviation) corresponds to a spatial resolution of 26 μm in diameter. The field stop size is shown below the graph. Figure 23 and Figure 24 The data for CD45 and PD1 (from the same experiment) are shown.
[0163] Data shows that the present invention has a spatial detection capability corresponding to approximately 1-4 cells.
[0164] Example 5: This invention provides quantitative performance in clinically relevant assays. method The steps to use and Figures 10-14 The diagrams in the upper part are similar to those in the upper part.
[0165] Breast cancer tissue microarray (TMA): TMA BR1504a obtained from US Biomax, Inc.; H&E staining images obtained from the US Biomax website (World Wide Web). www (biomax.us / tissue-arrays / Breast / BR1504a). (Source: biomax.us / tissue-arrays / Breast / BR1504a) Figure 25 The slides shown in the left image are identical to those in the goat α rabbit (Life Tech) labeled with Her2 primary antibody 29D8 (rabbit mAb, CST) and Alexa 594. Histone H3, ribosomal protein S6, estrogen receptor, progesterone receptor, mouse IgG isotype control, and rabbit IgG isotype control were also counted (data not shown). Her2 pathologist score for TMA BR1504a was provided by US Biomax, Inc. (www.biomax.us / tissue-arrays / Breast / BR1504a). Staining was performed with Her2 primary antibody 29D8 (rabbit mAb, CST) and Alexa 594 labeled with goat α rabbit (Life Tech). Although other rabbit primary antibodies were used in the primary mixture, the fluorescence from these antibodies was negligible compared to Her2 fluorescence. Pixel intensity sums (at λ=594) were obtained using ImageJ software. To do this, set the background value to intensity = 0 and the maximum intensity to intensity = 255. Display the sum of the pixel intensities for each ROI.
[0166] Here, fluorescence is first used to image the sample, and then a digital count of protein expression is performed on the sample.
[0167] result Figure 25 (Left image) shows a tissue microarray (TMA) of breast tumor tissue containing varying levels of Her2 protein, as shown in the micrograph (middle image), which was identified by IHC staining for Her2 fluorescence. The right image shows a magnified view of a single region from the middle image, stained with a mixture of multiplexed antibodies.
[0168] Figure 26 This displays the relationship between nCounter® count data and Her2 status (ASCO-CAP criterion) for 48 representative regions. Figure 27 Plot the nCounter® counts and pixel intensity sums (x 10) for the 48 regions mentioned above. 3 The relationship between ).
[0169] These numerical counts show a correlation with the visual Her2 state score according to the ASCO-CAP criteria (R2=0.51). Figure 26 Compared to ), it was highly correlated with fluorescence intensity (R² = 0.92). Figure 27 ).
[0170] Example 6: This invention reveals the abundance of specific cell types in tissue samples. The steps to use and Figures 10-14 Similar to those illustrated in the upper part, the process involves first using fluorescence to image the melanoma sample attached to a glass slide, and then performing a digital count of protein expression from the sample.
[0171] Figure 28 Micrographs showing the overall histological morphology of melanoma samples established using dual-color fluorescence analysis of CD3 (an immune cell marker, shown in red) and DAPI (nucleus, shown in blue). Expression data using a mixture of 30 antibodies were derived from 10 regions defined by white boxes. Figure 29 Showing from Figure 28 The image shows exemplary nCounter® counts of a mixture of 30 multiplexed oligoantibodies across 10 target regions (ROIs) in a melanoma sample. Counts of 13 biomarkers are displayed, each with an expression count above background levels. Regions 5, 6, and 7, identified as “rich in immune infiltrators,” showed the highest expression of T-cell biomarkers and T-cell regulatory biomarkers.
[0172] These data show that the present invention provides spatially resolved detection of a variety of protein biomarkers (at least 30 here). By increasing the number of protein probes (antibodies) used, up to 800 different protein biomarkers can be detected with similar resolution.
[0173] Example 7: Digital mirror device (DMD) capable of irradiating single cells Figures 30 and 31 are photomicrographs showing UV irradiation of single cells in a tonsil tissue sample using a digital microscope (DMD).
[0174] These data demonstrate that the present invention is capable of single-cell resolution when using DMD.
[0175] Example 8: The cartridge can irradiate the entire sample and release signal oligonucleotides from the probes that bind to the entire sample. Figure 34 This illustration shows an embodiment in which an entire tissue or sample is irradiated, for example, using a standard laboratory UV gel box. Here, an FFPE tissue slide is placed on a light plate, a buffer solution (TBS) covering the FFPE tissue is maintained using a wax pen, and UV light is applied (276-362 nm, e.g., 302 nm, ~5 mW / cm²). 2 The antibody was applied to the tissue via a glass slide (1 mm thick). Data showed that within approximately 1 minute of UV exposure, most of the signaling oligonucleotides were released from the antibody bound to FFPE. Counts were normalized to a positive control.
[0176] Example 9: Irradiation from a microscope can illuminate the target region in a sample and release signaling oligonucleotides from the probe that binds to the target region. Figure 35 This illustrates an embodiment in which a portion of a tissue or sample is irradiated, for example, under a microscope, i.e., UV lysis (time titration experiment) is performed under a microscope. This contrasts with the experiment in Example 8, in which the entire sample is irradiated. Here, the UV LED (at 365 nm) is at approximately ~150 mW / cm². 2 A 20x objective lens was applied. UV irradiation was applied to the entire tissue area identified by previous bright-field imaging with fluorescence (~590 nm excitation). Within approximately 1 second of UV exposure per field of view (FOV), most of the signaling oligonucleotides were released from the FFPE-bound probe. The cartridge experiment of Example 8 was used as a non-spatial-resolved 100% release control. Counts are normalized ratios relative to the positive control. Blue: Microscopic data for variable exposure times; Red: Cartridge 2.5-minute exposure data. Photographs and schematic diagrams illustrating the microscopy apparatus are also shown.
[0177] Figure 36 The signal oligonucleotides were shown to be released from a uniformly distributed antihistone (H3) antibody upon binding to a lung tissue sample. The tissue was exposed to UV (365 nm, ~150 mW / cm²) for 1 second. 2 (20 x objectives) / field of view (FOV), which is approximately 450 μm x 330 μm = 0.15 mm. 2The "macro-volume" used to collect the effluent is approximately 70 μl. This reduces the detection limit to (FOV / 5) ~99 μm x 99 μm, collecting approximately 5 μl of effluent. Therefore, in this embodiment, the detection limit is approximately a 10-cell x 10-cell niche. These data show that the antibody signal is proportional to the spatially resolved irradiated area (FOV) and evaluate the "macro-fluidics" detection limit (LOD).
[0178] Figure 37 This illustrates an implementation where a portion of a tissue or sample is irradiated under a microscope, i.e., UV lysis (irradiation area titration) is performed under a microscope, targeting multiple targets. UV lysis of multiple targets in the tissue is shown: two positive targets (histone H3 and ribosome S6) and eight negative targets. Only one negative target (0x40) shows high background. Data for 0, 1, 4, 9, and 16 fields of view are displayed.
[0179] Example 10: The target region can be pre-identified using labeling technology. Then, the target region is irradiated, and the signal oligonucleotide is released from the probe that has bound to the pre-identified target region. Figure 38 One implementation is shown, in which a target region in a tissue (e.g., a breast cancer sample) is first identified for expressing a biomarker (here, Her2), and then the target region is irradiated (e.g., with UV) to release signaling oligonucleotides via self-binding probes. The data shown compare the amounts of signaling oligonucleotides for two targets (here, Her2 and histone H3) released from two locations: a target region pre-identified as Her2+ and a target region pre-identified as Her2-.
[0180] Example 11: Samples embedded in the flow cell provide elution collection from the entire sample, not only from the irradiated target region but also from regions releasing signal oligonucleotides. Figure 39 One embodiment is shown, in which tissue is embedded in a flow cell. Here, FFPE tissue embedded in a microfluidic flow cell (9 mm circular chamber, 100 μm high, with a volume of approximately 25 μl [approximately 75 μl when the flow cell has a height of 300 μm]) is controlled by an injection pump. UV lysis is performed within the flow cell, and the elution profile is shown as irradiation of one region (9 FOV) and elution, followed by irradiation of another region (9 FOV) and elution. Data for multiple fractions are shown. As with the data from Example 10, the expression of fluorescent markers in the target regions is pre-identified here.
[0181] Example 12: Embedding samples in flow cells containing small wells within the target region provides efficient collection of elution from the irradiated target region and the region where signaling oligonucleotides are released, rather than from the entire sample. Figure 40 This section shows an embodiment in which a tissue package is embedded in a flow cell with small pores. Here, elution occurs directly above the target region. The 0.4–1 mm diameter pores above the fluid chamber allow for the collection of eluent (e.g., a 5 μl collection volume). Nine-well, 96-well, and 12-well patterns (for tissue microarrays (TMA)) were tested. Fluorescence images were created by combining multiple fields of view. Photographs and schematic diagrams illustrating the device structure are also shown.
[0182] Figures 41A-41C The implementation using a flow cell with small orifices shows a significant improvement in signal-to-noise ratio compared to collecting the eluent across the entire self-organized surface. Data shows that collecting the eluent through an orifice above the target region increases the signal-to-noise ratio by approximately 7 times. In this implementation, a 1 mm diameter orifice above the fluid flow cell (25 μl chamber) is used to collect the eluent (5 μl fraction). Data for multiple fractions are shown.
[0183] Figures 42A-42C Data is shown using flow cells with small orifices (12 or 96-well configuration). The data shows that collecting the eluent through the orifices above the target region increases the signal-to-noise ratio by approximately 7-fold. In this embodiment, the field of view is focused on the center of the orifice, and 5 μl of eluent is eluted per orifice.
[0184] Figure 43A B shows a comparison of the background signal from the flow cell in which whole tissue elution was performed. Figure 43A (as in Example 11) and the background signal from the flow cell directly above the target region where elution occurs ( Figure 43B (Data). For example, in Figure 43A As seen, relative to Figure 43B The background seen therein is even more significant than the background of the entire organization's cleansing. Furthermore, Figure 43B The results showed no difference between incubation in the flow cell and in the non-flow cell.
[0185] Example 13: The released signaling oligonucleotides can be selected via a single tube / pipette, multiple tubes / pipettes, or an array of multiple tubes / pipettes. Figure 44 This is a schematic diagram illustrating eluent collection in an embodiment with an open surface for aspiration of multiple target regions. A multi-tube array for aspiration / dispensing of eluent is shown here, selected using a rotary valve. See also... Figure 47 .
[0186] Figure 45Includes photographs and diagrams showing one embodiment where the eluent is collected via a capillary (micro-aspirator). See also Figure 47 . Figure 46A And B shows from Figure 45 Data from the embodiment shown are provided, in which the eluent is collected via a capillary (micro-aspirator). This embodiment exhibits a significant improvement in signal-to-noise ratio: an increase of approximately 10-fold compared to flow cell elution via pores, and an increase of approximately 200-fold compared to whole tissue elution. Here, the LOD area is approximately 60 μm x 60 μm.
[0187] Example 14: A device incorporating both irradiation and elution capabilities can efficiently and accurately acquire nucleic acid and / or protein expression data for customizable target regions. Figure 48 This is a schematic diagram illustrating the illumination and collection of fluid by combining a capillary tube and a lens.
[0188] Example 15: Protein expression can be detected and quantified from a single cell. Figure 50 This figure shows protein expression data obtained from single cells or two cells using the methods and apparatus described herein. In the upper figure, S6 protein was detected and quantified from at least one cell, and in the lower figure, CD45 protein was detected and quantified from at least one cell.
[0189] Example 16: The methods and apparatus described herein provide accurate and efficient detection and quantification of spatially resolved multiplexed RNA targets and / or protein targets. In situ hybridization (ISH) was performed to hybridize DNA oligomer-based probes (“RNA probes”), each containing a target-binding domain, a signal oligonucleotide, and a photolyzable linker, with endogenous RNA. 5 μm FFPE HER2 3+ breast tissue sections were dewaxed in xylene, partially rehydrated in graded ethanol, and incubated in 70% ethanol at room temperature for 1 hour. The sections were then incubated at 37°C in 40 μg / ml proteinase K for 25 minutes. The tissues were then incubated at room temperature in 50% formamide / 2X SSC for 15 minutes, and hybridized overnight at 37°C in a 2X SSC solution containing 1 nM probe, 40% formamide, 1 mg / ml yeast tRNA, 10% dextran sulfate, and 0.2% BSA. After hybridization, the sections were subjected to two rigorous washes at 37°C with 50% formamide / 2X SSC for 25 minutes each. The sections were then processed using TO-PRO. ®-3 (Thermo Fisher Scientific) fluorescent nucleic acid dye staining was used to visualize tissue morphology. Focused UV light, guided by a digital micromirror device, was then used to self-probe cleave DNA signaling oligonucleotides in user-defined target areas (ROIs). For each tissue slice, two ROIs contained tumor tissue, two ROIs contained normal tissue, and two ROIs contained no tissue at all (the histological slide itself). After cleavage, the signaling oligonucleotides were collected, hybridized with nCounter® molecular barcodes, and analyzed by NanoString Technologies. ® nCounter ® The system performs digital counting. Hematologic and epithelial analysis (H&E) is performed on tissue sections to verify the region of interest (ROI) of tumor and normal tissue.
[0190] On serial sections, standard immunohistochemistry (IHC) was performed using protein probes, each containing an antibody as a target-binding domain, a DNA signaling oligonucleotide, and a photolyzable adapter. The sections were then treated with anti-rabbit Alexa 594 secondary antibody and TO-PRO. ® -3 (Thermo Fisher Scientific) fluorescent nucleic acid dye staining was used to visualize tissue morphology. Focused UV light, guided by a digital micromirror device (DMD), was then used to lyse DNA signaling oligonucleotides at user-defined ROIs using self-probes. For each tissue section, two ROIs contained tumor tissue, one ROI contained normal tissue, and two ROIs contained no tissue at all (the histological slide itself). ROIs were matched to those selected for ISH probe lysis. After lysis, signaling oligonucleotides from protein targets were mixed with signaling oligonucleotides from RNA targets and quantified as described above. H&E was performed on the tissue sections to verify the correct matching of ROIs between tumor and normal tissues and between ISH and IHC tissues.
[0191] Figure 51 This image shows the ROIs sampled from consecutive sections of the same tumor sample. Regions 1-4 are not shown in this image but were taken from tissue portions that do not contain any tissue (negative control - "no tissue"). Regions 5-8 contain a small number of tumor cells ("normal tissue"). Regions 9-12 contain a large number of tumor cells ("tumor").
[0192] Figure 52The chart shows the counts obtained for 6 of the 9 RNA probes included in the assay. For each ROI, samples were collected before UV irradiation (“-UV” dataset) and before positive UV samples were collected from the same region (“+UV” dataset). Background levels were obtained when UV was not applied to the samples, thus showing the UV dependence of the obtained signal. Background counts are given for ROIs that are +UV but not tissue-targeted (i.e., ROIs 1-4 – “No Tissue”). Low HER2 probe counts are given for regions that are predominantly normal tissue (i.e., ROIs 5-8 – “Normal Tissue”). Higher HER2 counts are given for regions that are predominantly tumor tissue (i.e., ROIs 9-12 – “Tumor”). A similar but less significant increase is seen for the ribosomal S6 probe (green bar in the chart). RNAs targeted by additional control probes that are not expected to be highly expressed in this tissue type are given consistent counts, showing no difference in levels between normal and tumor tissues. These control probes were designed to target CD45, PSA (prostate-specific antigen), and two distinct ERCC sequences. For clarity, Figure 53 show Figure 52 The data displayed shows the mean and standard deviation.
[0193] These RNA probe samples were also run simultaneously with protein probes analyzing sample regions of tumor samples. For this purpose, both RNA and protein probes were simultaneously hybridized with nCounter® molecular barcodes and processed via NanoString Technologies. ® nCounter ® The system performs digital counting. The measured count is displayed on the screen. Figure 54 In the tumor region, compared to the normal region, increased HER2 RNA probe counts (red bars in the top image) and protein probe counts (red and orange bars in the bottom image) were observed. Only +UV samples are shown. As described above, -UV control samples are not shown in this figure because they give background counts (similar to "no tissue" counts). ROIs 6 and 8 were removed from this analysis because no matching protein probe samples were obtained. Therefore, signal oligonucleotides from protein probes and signal oligonucleotides from RNA probes can be detected and quantified together.
[0194] Example 17: Compared with single-stranded probes, some double-stranded probes have a higher signal-to-noise ratio. DNA probes (which recognize and bind to mRNA) were in situ hybridized with RNA in 5 μm FFPE tissue as described in Example 16. Whole tissue sections (mounted on separate slides) were UV-lysed for 3 minutes in 2X SSC + 0.1% Tween 20 using a UV lamp box (cassette). After lysis and release of the signal oligonucleotides, they were collected via pipette and detected as in Example 16. Counts of single-stranded DNA probes, partially double-stranded DNA probes, and probe-free controls in HER2 3+ breast and tonsil tissues are shown in the figure. Figure 55 In the image above, the signal-to-noise ratio (SNR) is determined by dividing the count by the average background count (average ERCC count). See [link to relevant documentation]. Figure 55 See the image below.
[0195] Example 18: Adding salmon sperm DNA to improve probe hybridization The DNA probe (which recognizes and binds to mRNA) was in situ hybridized with RNA in 5 μm FFPE tissue as described above. During hybridization, 1 mg / ml sonicated denatured salmon sperm DNA was used instead of yeast tRNA. Slides were hybridized with a 2X SSC solution of 1 nM probe, 40% formamide, 1 mg / ml sonicated denatured salmon sperm DNA, 10% dextran sulfate, and 0.2% BSA. UV lysis and signal oligonucleotide collection and detection were performed as described in Example 17. Single-stranded DNA probes were visualized in HER2 3+ mammary glands and tonsils. Figure 56 The signal-to-noise ratio is determined by dividing the count by the average background count (average ERCC count).
[0196] Example 19: The PSA (prostate-specific antigen) RNA probe is highly specific. The DNA probe (which recognizes and binds to mRNA) was in situ hybridized with RNA in 5 μm FFPE prostate slices as described above. Incubation at 97°C for 10 minutes in MES was used instead of 1 hour of ethanol incubation. UV lysis, signal oligonucleotide collection and detection, and signal-to-noise ratio calculation were performed as described in Example 17. Counts and ratios were displayed. Figure 57 middle.
[0197] Example 20: Increased probe specificity at non-standard sub-nM concentrations Generally, in situ hybridization (ISH) probes used to recognize RNA hybridize at 5-200 nM. Surprisingly, the nucleic acid recognition probes of the present invention perform best at 0.2 nM or less, a concentration as low as 1 / 25 to 1 / 1000 of the standard ISH probe concentration.
[0198] The DNA probes were in situ hybridized with RNA in 5 μm slices of FFPE HER2 3+ breast cancer samples as described above. Probes were used at concentrations of 5, 1, 0.2, and 0.4 nM. UV lysis, signal oligonucleotide collection and detection, and fold change calculations were performed as described in Example 17.
[0199] Figure 58 The counts showed a decrease as probe concentration decreased (top figure). However, unexpectedly, when the probes hybridized at sub-nM concentrations, the signal-to-noise ratio significantly increased when the positive probe counts were compared to the negative control probe counts.
Claims
1. A method comprising the following steps: (1) Contact at least one protein target in a tissue sample with at least one probe comprising a target-binding domain, a signal oligonucleotide and a photolyzable motif located between the target-binding domain and the signal oligonucleotide; (2) Irradiate specific locations of the immersed tissue sample with light sufficient to release the signal oligonucleotide into the fluid; (3) The released signal oligonucleotides are collected by using capillary aspiration of a solution located directly above the irradiated site, wherein the aspiration is performed using a capillary no more than 100 μm above the immersed tissue sample. and (4) Identify the released signaling oligonucleotides to detect at least one protein target at the specific location in the irradiated tissue sample.
2. The method of claim 1, wherein the detection includes determining the identity and abundance of the at least one protein target.
3. The method of claim 2, wherein the at least one protein target comprises at least two different protein targets or at least two copies of the same protein target.
4. The method of claim 3, wherein the detection includes comparing the abundance of each different protein target.
5. The method of claim 1, further comprising repeating at least steps (2)-(4) at at least a second specific location in the tissue sample.
6. The method of claim 5, wherein the detection comprises comparing the abundance of the at least one protein target at the specific location with that at the at least second specific location.
7. The method of claim 6, wherein the specific location contains the same cell type as the at least second specific location.
8. The method of claim 6, wherein the specific location and the at least second specific location comprise different cell types.
9. The method of claim 7 or 8, wherein the cell type is independently selected from normal cells and abnormal cells.
10. The method of any one of claims 1-8, wherein the tissue sample is directly or indirectly fixed to a microscope slide.
11. The method of claim 10, wherein the tissue sample is a tissue section 2-1000 μm thick.
12. The method of claim 11, wherein the tissue sections are obtained from formalin-fixed paraffin-embedded samples.
13. The method of any one of claims 1-8, wherein the tissue sample comprises at least one cell, wherein the at least one cell is a cultured cell, a primary cell, or a dissociated cell from an explant.
14. The method of claim 1, wherein the tissue sample is fixed or unfixed.
15. The method of any one of claims 1-8, wherein the tissue sample is stained or labeled prior to step (2) so that subcellular, cellular or tissue-related structures in the stained or labeled tissue sample can be visualized.
16. The method of any one of claims 1-8, wherein the signal oligonucleotide is a single-stranded nucleic acid or a partially double-stranded nucleic acid.
17. The method of any one of claims 1-8, wherein the irradiation is provided by a light source selected from arc lamps, lasers, focused UV light sources and light-emitting diodes.
18. The method of any one of claims 1-8, wherein the irradiation is performed on at least one subcellular structure at the specific location of the tissue sample.
19. The method of claim 18, wherein the detection includes determining the abundance of the at least one protein target in the at least one subcellular structure of the tissue sample.
20. The method of any one of claims 5-8, wherein the irradiation is provided by a light source selected from an arc lamp, a laser, a focused UV light source and a light-emitting diode, and the light source irradiates at least one subcellular structure at the specific location of the tissue sample and at least one subcellular structure at the at least second specific location of the tissue sample.
21. The method of claim 20, wherein the detection comprises comparing the abundance of at least one protein target in at least one subcellular structure at the specific location of the tissue sample with the abundance of at least one protein target in at least one subcellular structure at at least a second specific location of the tissue sample.
22. The method of any one of claims 1-8, wherein the target-binding domain is selected from antibodies, peptides, aptamers, and peptide-like substances.
23. The method of any one of claims 1-8, wherein the detection comprises polymerase reaction, reverse transcriptase reaction, hybridization with oligonucleotide microarray, mass spectrometry, hybridization with fluorescent molecular beacons, sequencing reaction, or hybridization with molecular barcodes.
24. The method of any one of claims 1-8, wherein the protein target is an intact protein or peptide.
25. The method of any one of claims 1-8, wherein the capillary comprises an optical device capable of transmitting light to the specific location of the tissue sample.
26. The method of claim 25, wherein the light is UV light.
27. The method of any one of claims 1-8, wherein the collected signal oligonucleotide is added to a solution containing an anionic polymer.
28. The method of any one of claims 1-8, wherein the method further comprises irradiating the target area using a laser scanning device.
29. The method of any one of claims 1-8, wherein the method further comprises illuminating the target area using a digital mirror device.
30. The method of any one of claims 1-8, wherein the method provides for simultaneous spatially resolved protein detection of a sample.
31. The method of any one of claims 1-8, wherein the tissue sample is attached to a glass slide and fluorescence imaging is first used, followed by digital counting of protein expression from the sample.
32. The method of any one of claims 1-8, wherein the probe is provided at a concentration of 5 nM or lower.
33. The method of claim 32, wherein the probe is provided at a concentration of 1 nM or lower.
34. The method of claim 33, wherein the probe is provided at a concentration of 0.4 nM or lower.
35. The method of claim 34, wherein the probe is provided at a concentration of 0.2 nM or lower.
36. The method of claim 27, wherein the anionic polymer is dextran sulfate or salmon sperm DNA.
Citation Information
Patent Citations
Methods for detection and quantification of analytes in complex mixtures
US20030013091A1
Methods for detection and quantification of analytes in complex mixtures
US20070166708A1
Nanoreporters and methods of manufacturing and use thereof
US20100015607A1
Stable nanoreporters
US20100047924A1
Methods and computer systems for identifying target-specific sequences for use in nanoreporters
US20100112710A1
